AELIS.PA Aelis Farma SA

Healthcare Biotechnology Euronext Paris
1.02 EUR
Close of Nov 7, 2026
0.6100 2.30
Market cap
EUR 13.9M
P/E
-
P/B
6.01x
ROE
-417.2%
Dividend yield
-
Fundamental score
1.0/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is AELIS.PA undervalued?

Graham number

The Graham number of Aelis Farma SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aelis Farma SA fundamental analysis

3 of 11 checks passed

ROE 0/2

The stock's ROE indicates a negative return (-144.4%) on shareholders' equity, suggesting poor financial performance.

ROA 0/2

The stock's ROA (-36.61%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

PBV 0/2

The stock's elevated P/BV ratio (8.02x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

DER 2/2

The stock has a minimal amount of debt (19%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

Revenue Growth 0/2

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Net Profit Growth 0/2

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

Assets Growth 1/2

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

Graham Number 0/1

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

Dividend Growth 0/2

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

Dividend 0/2

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Buffet Intrinsic Value 1/1

Warren Buffett's formula suggests that the company's stock is undervalued (17), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Aelis Farma SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aelis Farma SA

Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observ…

Full company profile